Eliem Therapeutics, Inc. (NASDAQ:ELYM) Expected to Post Q1 2023 Earnings of ($0.16) Per Share

Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Rating) – Analysts at SVB Leerink issued their Q1 2023 earnings estimates for shares of Eliem Therapeutics in a research report issued on Monday, March 6th. SVB Leerink analyst M. Goodman expects that the company will earn ($0.16) per share for the quarter. The consensus estimate for Eliem Therapeutics’ current full-year earnings is ($1.60) per share. SVB Leerink also issued estimates for Eliem Therapeutics’ Q2 2023 earnings at ($0.16) EPS, Q3 2023 earnings at ($0.16) EPS, Q4 2023 earnings at ($0.16) EPS, FY2023 earnings at ($0.65) EPS, FY2024 earnings at ($0.50) EPS, FY2025 earnings at ($0.75) EPS and FY2026 earnings at ($1.15) EPS.

Separately, HC Wainwright restated a “neutral” rating and set a $6.00 target price on shares of Eliem Therapeutics in a research note on Wednesday.

Eliem Therapeutics Stock Performance

ELYM opened at $3.45 on Thursday. The stock has a market capitalization of $91.67 million, a P/E ratio of -2.01 and a beta of 0.53. The company’s 50-day simple moving average is $3.54 and its two-hundred day simple moving average is $3.19. Eliem Therapeutics has a 52-week low of $2.21 and a 52-week high of $11.51.

Hedge Funds Weigh In On Eliem Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BML Capital Management LLC bought a new position in shares of Eliem Therapeutics in the 4th quarter worth approximately $6,698,000. Driehaus Capital Management LLC lifted its stake in shares of Eliem Therapeutics by 58.3% in the 4th quarter. Driehaus Capital Management LLC now owns 551,942 shares of the company’s stock worth $2,026,000 after purchasing an additional 203,371 shares during the period. Millennium Management LLC bought a new position in shares of Eliem Therapeutics in the 2nd quarter worth approximately $272,000. Silverarc Capital Management LLC bought a new position in shares of Eliem Therapeutics in the 1st quarter worth approximately $741,000. Finally, Atom Investors LP lifted its stake in shares of Eliem Therapeutics by 154.9% in the 3rd quarter. Atom Investors LP now owns 67,074 shares of the company’s stock worth $217,000 after purchasing an additional 40,765 shares during the period. Institutional investors own 63.29% of the company’s stock.

Eliem Therapeutics Company Profile

(Get Rating)

Eliem Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial.